Log in to your Inderes Free account to see all free content on this page.
AlzeCure Pharma
1.95 SEK
+2.64 %
Less than 1K followers
ALZCUR
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+2.64 %
+3.73 %
-2.75 %
-3.71 %
-54.34 %
+36.47 %
-46.67 %
-68.17 %
-79.46 %
AlzeCure Pharma is a pharmaceutical company that researches and develops small molecule drug candidates for the treatment of diseases of the central nervous system, with a particular focus on Alzheimer's and chronic pain. The company is developing several parallel projects where the technology and research are based on its own drug platform. AlzeCure Pharma is headquartered in Huddinge, Sweden.
Read moreMarket cap
223.51M SEK
Turnover
46.9K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
26.2.
2026
Annual report '25
5.5.
2026
Interim report Q1'26
14.5.
2026
General meeting '26
All
Press releases
3rd party
ShowingAll content types
AlzeCure Pharma selected to present at the Bio-Neuroscience conference in Amsterdam
AlzeCure receives payment of EU grant for Phase 2 clinical trial with NeuroRestore ACD856 for Alzheimer's disease
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio